Mass Medical Angels
Status
ACTIVE
Global HQ
Brookline, United States
Countries of investment
- USA
Investment stages
- Seed
Industries
- Health Tech
- Biotechnology
About
Mass Medical Angels (MA2) is a distinguished seed stage investor group dedicated to advancing life science and healthcare innovations. With a keen focus on identifying and nurturing early-stage life science companies, MA2 offers not only essential financing but also strategic mentoring to help these startups secure additional funding and achieve sustainable growth. By leveraging a network of experienced industry professionals, Mass Medical Angels empowers entrepreneurs to navigate the complexities of the healthcare landscape, ultimately striving to enhance patient outcomes and drive transformative advancements in the field.
Mass Medical Angels (MA2) is a distinguished seed stage investor group dedicated to advancing life science and healthcare innovations. With a keen focus on identifying and nurturing early-stage life science companies, MA2 offers not only essential financing but also strategic mentoring to help these startups secure additional funding and achieve sustainable growth. By leveraging a network of experienced industry professionals, Mass Medical Angels empowers entrepreneurs to navigate the complexities of the healthcare landscape, ultimately striving to enhance patient outcomes and drive transformative advancements in the field.
Investment Thesis
Mass Medical Angels (MA2) is a Seed stage investor group exclusively focused on life science and healthcare investments. The mission is to bring more clinical tools to the marketplace, while attaining superior returns for investors. They provide financing and mentoring to early stage lifescience companies so that they can obtain further funding, reach positive cashflows or get acquired.
Manager's Experience
With extensive experience in the healthcare and technology sectors, the fund manager has successfully led numerous investments across North America and Europe. They have executed over 30 deals, focusing primarily on early to growth-stage companies. Their strategic style emphasizes a data-driven approach, enabling informed decision-making and fostering innovation. Notable exits include several high-profile acquisitions, underscoring their ability to identify and nurture high-potential businesses.
Team
Richard Anders
Michele Bernier
Roger Kitterman
Peter Choo
Kevin Molloy
Jeffrey Chizmas
Girija Goyal
George Hunnewell